Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Tumor, Solid

In brief

A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Key facts

Study ID

NCT04840394

Run by

Eikon Therapeutics

People needed

1

Starts

2021-06-22

Expected to finish

2024-09-30

Last updated by the study team

2025-11-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed advanced or metastatic solid tumors that have disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Note: there is no limit to the number of prior treatment regimens
• Evidence of progressive disease (PD) within 3 months of signing the informed consent form.
• Have measurable disease

You may not qualify if…

• Has disease that is suitable for local therapy administered with curative intent.
• Prior exposure to TLR7 agonists, TLR8 agonists, TLR 7/8 dual agonists, and TLR9 agonists.
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Florida Cancer Specialists — Sarasota, Florida, United States
• START MidWest — Grand Rapids, Michigan, United States
• START — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.